Viewing Study NCT01846793

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:22 AM
Ignite Modification Date: 2026-02-22 @ 5:22 PM
Study NCT ID: NCT01846793
Status: COMPLETED
Last Update Posted: 2017-03-10
First Post: 2013-05-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Sponsor: Nymox Corporation
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Benign Prostatic Hyperplasia View
None BPH View
None Lower Urinary Tract Symptoms (LUTS) View
None LUTS View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Benign prostatic hyperplasia View
None BPH View
None Lower urinary tract symptoms View
None LUTS View
None LUTS secondary to BPH View
None LUTS/BPH View
None Benign prostatic obstruction (BPO) View
None BPO View
None Bladder outlet obstruction View
None BOO View